Novel Dihydroisoquinolinone-Amide Compounds as GIPR Agonists for Treating Type 2 Diabetes Mellitus and Obesity

Key Points

• The research focuses on developing new dihydroisoquinolinone-amide compounds that act as GIPR agonists.
• Synthesize novel dihydroisoquinolinone-amide compounds
• Evaluate these compounds for their action as GIPR agonists
• Assess effectiveness in managing type 2 diabetes and obesity.
• Identified dihydroisoquinolinone-amide compounds that activate GIPR
• Demonstrated potential for lowering blood sugar levels
• Showed effects on weight management in obesity models.